Literature DB >> 10096296

A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments.

G A Huls1, I A Heijnen, M E Cuomo, J C Koningsberger, L Wiegman, E Boel, A R van der Vuurst de Vries, S A Loyson, W Helfrich, G P van Berge Henegouwen, M van Meijer, J de Kruif, T Logtenberg.   

Abstract

A single-chain Fv antibody fragment specific for the tumor-associated Ep-CAM molecule was isolated from a semisynthetic phage display library and converted into an intact, fully human IgG1 monoclonal antibody (huMab). The purified huMab had an affinity of 5 nM and effectively mediated tumor cell killing in in vitro and in vivo assays. These experiments show that nonimmunized phage antibody display libraries can be used to obtain high-affinity, functional, and clinically applicable huMabs directed against a tumor-associated antigen.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10096296     DOI: 10.1038/7023

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  19 in total

Review 1.  Generation and production of engineered antibodies.

Authors:  Sergey M Kipriyanov; Fabrice Le Gall
Journal:  Mol Biotechnol       Date:  2004-01       Impact factor: 2.695

Review 2.  Demystified...recombinant antibodies.

Authors:  K A Smith; P N Nelson; P Warren; S J Astley; P G Murray; J Greenman
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

3.  A Fluorescent Imaging Probe Based on a Macrocyclic Scaffold That Binds to Cellular EpCAM.

Authors:  Kazuhiro Iwasaki; Yuki Goto; Takayuki Katoh; Taro Yamashita; Shuichi Kaneko; Hiroaki Suga
Journal:  J Mol Evol       Date:  2015-11-09       Impact factor: 2.395

Review 4.  Selection strategies for anticancer antibody discovery: searching off the beaten path.

Authors:  David Sánchez-Martín; Morten Dræby Sørensen; Simon Lykkemark; Laura Sanz; Peter Kristensen; Erkki Ruoslahti; Luis Álvarez-Vallina
Journal:  Trends Biotechnol       Date:  2015-03-26       Impact factor: 19.536

5.  A novel in vivo method for isolating antibodies from a phage display library by neuronal retrograde transport selectively yields antibodies against p75(NTR.).

Authors:  Hiroaki Tani; Jane K Osbourn; Edward H Walker; Robert A Rush; Ian A Ferguson
Journal:  MAbs       Date:  2013-04-02       Impact factor: 5.857

6.  Use of real-time polymerase chain reaction to identify cell- and tissue-type-selective peptides by phage display.

Authors:  David L Jaye; Frederick S Nolte; Luca Mazzucchelli; Cissy Geigerman; Adil Akyildiz; Charles A Parkos
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

7.  Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished.

Authors:  Victor W van Beusechem; Jacques Grill; D C Jeroen Mastenbroek; Thomas J Wickham; Peter W Roelvink; Hidde J Haisma; Martine L M Lamfers; Clemens M F Dirven; Herbert M Pinedo; Winald R Gerritsen
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

8.  Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.

Authors:  Bin Liu; Fraser Conrad; Audrey Roth; Daryl C Drummond; Jeff P Simko; James D Marks
Journal:  J Mol Med (Berl)       Date:  2007-06-07       Impact factor: 4.599

9.  In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule.

Authors:  W Steve Ammons; Robert J Bauer; Arnold H Horwitz; Zhi J Chen; Eddie Bautista; Harry H Ruan; Marina Abramova; Kristen R Scott; Russell L Dedrick
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

10.  Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells.

Authors:  Edwin Bremer; Douwe Samplonius; Bart-Jan Kroesen; Linda van Genne; Lou de Leij; Wijnand Helfrich
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.